Advertisement
UK markets closed
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     
  • CRUDE OIL

    83.41
    +1.51 (+1.84%)
     
  • GOLD FUTURES

    2,337.40
    -9.00 (-0.38%)
     
  • DOW

    38,480.12
    +240.14 (+0.63%)
     
  • Bitcoin GBP

    53,569.32
    +243.76 (+0.46%)
     
  • CMC Crypto 200

    1,436.24
    +21.48 (+1.52%)
     
  • NASDAQ Composite

    15,706.18
    +254.87 (+1.65%)
     
  • UK FTSE All Share

    4,378.75
    +16.15 (+0.37%)
     

Investors in Judges Scientific (LON:JDG) have made a massive return of 486% over the past five years

We think all investors should try to buy and hold high quality multi-year winners. And we've seen some truly amazing gains over the years. Just think about the savvy investors who held Judges Scientific plc (LON:JDG) shares for the last five years, while they gained 431%. If that doesn't get you thinking about long term investing, we don't know what will. It's also good to see the share price up 18% over the last quarter.

So let's assess the underlying fundamentals over the last 5 years and see if they've moved in lock-step with shareholder returns.

See our latest analysis for Judges Scientific

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

ADVERTISEMENT

Over half a decade, Judges Scientific managed to grow its earnings per share at 51% a year. The EPS growth is more impressive than the yearly share price gain of 40% over the same period. Therefore, it seems the market has become relatively pessimistic about the company.

The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).

earnings-per-share-growth
earnings-per-share-growth

It's probably worth noting that the CEO is paid less than the median at similar sized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. This free interactive report on Judges Scientific's earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further.

What About Dividends?

It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. As it happens, Judges Scientific's TSR for the last 5 years was 486%, which exceeds the share price return mentioned earlier. This is largely a result of its dividend payments!

A Different Perspective

It's nice to see that Judges Scientific shareholders have received a total shareholder return of 46% over the last year. Of course, that includes the dividend. That gain is better than the annual TSR over five years, which is 42%. Therefore it seems like sentiment around the company has been positive lately. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. It's always interesting to track share price performance over the longer term. But to understand Judges Scientific better, we need to consider many other factors. To that end, you should be aware of the 1 warning sign we've spotted with Judges Scientific .

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on GB exchanges.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.